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Despite type 2 diabetes mellitus (T2D) is commonly considered a detrimental factor in dialysis, its 
clear effect on morbidity and mortality on waitlisted patients for kidney transplant (KT) has never 
been completely elucidated. We performed a retrospective analysis on 714 patients admitted to 
wait-list (WL) for their first kidney transplant from 2005 to 2010. Clinical characteristics at registration 
in WL (age, body mass index -BMI-, duration and modality of dialysis, underlying nephropathy, 
coronary artery -CAD- and/or peripheral vascular disease), mortality rates, and effective time on WL 
were investigated and compared according to T2D status (presence/absence). Data about therapy 
and management of T2D were also considered. At the time of WL registration T2D patients (n = 86) 
were older than non-T2D (n = 628) (58.7 ± 8.6 years vs 51.3 ± 12.9) with higher BMI (26.2 ± 3.8 kg/m2 vs 
23.8 ± 3.6), more frequent history of CAD (33.3% vs 9.8%) and peripheral vascular disease (25.3% vs 
5.8%) (p < 0.001 for all analyses). Considering overall population, T2D patients had reduced survival 
vs non-T2D (p < 0.001). Transplanted patients showed better survival in both T2D and non-T2D groups 
despite transplant rate are lower in T2D (75.6% vs 85.8%, p < 0.001). T2D was also associated to 
similar waiting time but longer periods between dialysis start and registration in WL (1.6 years vs 
1.2, p = 0.008), comorbidity-related suspension from WL (571 days vs 257, p = 0.002), and increased 
mortality rate (33.7% vs 13.9% in the overall population, p < 0.001). In T2D patients admitted to 
WL, an history of vascular disease was significantly associated to low patient survival (p = 0.019). 
In conclusion, T2D significantly affects survival also on waitlisted patients. Allocation policies in 
T2D patients may be adjusted according to increased risk of mortality and WL suspension due to 
comorbidities.
Type 2 diabetes mellitus (T2D) represents a real public health problem according to its increasing incidence and 
the severity of the disease with multi-organic  involvement1. T2D long-term complications include disability, 
reduced quality of life, premature death, and end-stage kidney disease (ESKD)2 with a consequent spreading 
percentage of dialytic patients affected by  T2D3. In this population a multi-specialistic approach to prevent and 
manage T2D-related comorbidity is mandatory. Despite improvements over the last decade have leaded to an 
amelioration in survival rates, both diabetes and ESKD increased risk of mortality, particularly due to cardio-
vascular complications, especially in cases who needed renal-replacement  therapies2,4.
OPEN
1Renal Transplantation Center, “A. Vercellone”, Division of Nephrology Dialysis and Transplantation, Department 
of Medical Sciences, Città della Salute e della Scienza Hospital and University of Turin, Corso Bramante, 
88-10126 Turin, Italy. 2Immunogenetic and Transplant Biology Center, Department of Medical Sciences, Città della 
Salute e della Scienza Hospital and University of Turin, Turin,  Italy. 3These authors contributed equally: Caterina 
Dolla, Erika Naso and Alberto Mella. *email: luigi.biancone@unito.it
2
Vol:.(1234567890)
Scientific Reports |        (2020) 10:22000  | https://doi.org/10.1038/s41598-020-78938-3
www.nature.com/scientificreports/
KT is considered the gold standard for ESKD for its superiority to dialysis for all outcomes (quality of life, 
overall survival, economic costs)5,6 and, despite some authors suggested negative or “not-so-positive” results in 
T2D  patients7, recent reports outline favorable outcome also in T2D  patients8. On the other hand few studies are 
focused on T2D patients who could be considered eligible for KT, and none of them at the best of our knowledge 
have evaluated if WL time—a variable directly correlated to negative outcome both for patient and  KT7,8—could 
be influenced by the intrinsic T2D frailty for T2D-related comorbidities.
In this study we investigate the effect of T2D on morbidity and mortality on waitlisted patients also comparing 
the effective time on WL according to T2D status (presence/absence).
Results
Baseline characteristics. During the investigated period, 714 patients were registered in our WL and 86 
out of 714 (12%) were affected by T2D. Clinical characteristics are summarized in Table 1.
Briefly, at the admission patients in T2D group were older than non-T2D (58.7 ± 8.6 years vs 51.3 ± 12.9) 
with higher BMI (26.2 ± 3.8 kg/m2 vs 23.8 ± 3.6), more frequent history of CAD (33.3% vs 9.8%) and peripheral 
vascular disease (25.3% vs 5.8%) (p < 0.001 for all analyses). No differences were observed regarding dialysis 
length and modality.
Pharmacological treatment of T2D and cardiovascular characteristics of our T2D patients admitted to WL 
were reported in Table 2.
In detail, 48 out of 86 patients (55.8%) received insulin therapy, 5/86 (5.8%) were treated with oral anti-
diabetic drugs, and 22/86 (25.6%) followed diet alone. HbA1c value at the time of registration in WL were within 
the correct range of glycemic control [median HbA1c 50 mmol/mol (25° 40–75° 61)].
Despite a more frequent history of CAD and evidence of left ventricular hypertrophy in the majority of T2D 
patients (50/86, 58.1%), echocardiography assessment revealed a normal median ejection fraction [median 60% 
Table 1.  Characteristics and follow-up of studied population according to T2D presence/absence. Data are 
expressed as mean ± SD or median (25°–75° percentile) according to their distribution. *Calculated on the total 
for each single group.
T2D (n = 86) Non-T2D (n = 628) Total p
Age, years 58.7 ± 8.6 51.3 ± 12.9 52.2 ± 12.2  < 0.001
Sex (M/F ratio) 61/25 389/239 450/264 0.065
BMI, kg/m2 26.2 ± 3.8 23.8 ± 3.6 24 ± 3.6  < 0.001
Coronary artery disease, n (%) 25 (33.3) 56 (9.8) 81 (12.5)  < 0.001
Periferic vascular disease, n (%) 19 (25.3) 36 (6) 55 (7.4)  < 0.001
Kidney Transplantation, n (%) 65 (75.6)* 539 (85.8)* 604 (84.6)* 0.013
Living donors, n (%) 2/65 (3.1) 24/539 (4.4) 26/604 (4.3) 0.06
Donor age, years 62.2 ± 14.2 56.9 ± 15 58.1 ± 14.5 0.006
Death
Overall population, n (%) 29 (33.7) 87 (13.9) 116 (16.2)  < 0.001
No KT, n (%) 15 (71.4)* 43 (48.3)* 58 (52.7)* 0.047
Pre-transplant dialysis time, years 3.8 ± 2.5 4.7 ± 3.6 4.6 ± 3.7 0.18
Period of WL suspension, days 571 (289–1073) 257 (83.5–802) 286 (92.7–860.7) 0.002
Time between dialysis start and WL registration, years 1.6 (1.1–2.5) 1.2 (0.72–2.2) 1.3 (0.75–2.3) 0.008
Table 2.  Pharmacological and cardiovascular characteristics of T2D group. *Data are expressed as mean ± SD 
or median (25°–75° percentile) according to their distribution. PCI percutaneous coronary intervention, CABG 
coronary artery bypass grafting, HbA1c glycosylated haemoglobin.
T2D (n = 86)
Insulin therapy, n (%) 48 (55.8%)
Oral anti-diabetic drugs, n (%) 5 (5.8%)
Diet alone, n (%) 22 (25.6%)
Not specified, n (%) 11 (12.8%)
Left ventricular hypertrophy, n (%) 50 (58.1%)
PCI, n (%) 13 (15.1%)
CABG, n (%) 4 (4.7%)
Cerebrovascular accident, n (%) 9 (10.5%)
HbA1c, mmol/mol * 50 (40–61)
Ejection fraction, % * 60 (55–64)
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(25° 55–75° 64)]. Considering vascular disease, percutaneous coronary intervention (PCI) and coronary artery 
bypass grafting (CABG) were performed in 13/86 (15.1%) and 4/86 (4.7%) respectively; an history of cerebro-
vascular accident was also observed in 9/86 T2D patients (10.5%).
During the follow-up (mean 8.4 ± 3 years) 604 patients underwent KT (84.6%) with a significantly lower KT 
rate in T2D group (75.6% vs 85.8%, p = 0.013). The number of living donors was similar in each group but, in 
deceased donors, donor’s age was higher in T2D group.
Survival analysis. Survival rates were investigated both considering the f/up starting at the beginning of 
dialysis or at the time of registration in WL. Patients in T2D group had a reduced survival than non-T2D (Fig. 1 
a–b) and transplanted patients had a better survival than those who remain in WL (Fig. 2 a–b); comprehen-
sively, all transplanted patients had a better survival than those remaining on WL. This favorable outcome of 
KT patients was confirmed in the intra-group analysis both for T2D and non-T2D groups, despite T2D showed 
lower survival rates (Fig. 3).
Analyzing the possible impact of dialysis duration on survival we noted that patients who died during the f/
up have a longer dialysis history before the registration in WL [19.8 months (25° 10–75° 34.5) vs 15 months (25° 
8.9–75° 26.2), p < 0.01]; stratifying this data to patients who underwent KT this variable remained significant in 
the overall population and in non-T2D group.
Among both the overall population and the subgroup of patients who did not receive KT the mortality rate 
was significantly higher in T2D (Table 1); focusing on this group (which is not biased by transplant-related 
events) cardiovascular events and infections, as expected, were the most common causes of death in both T2D 
and non-T2D (Table 3). Cox regression analysis showed a 2.4 fold higher mortality risk (OR 2.4, IC 95% 1.5–3.6) 
in T2D vs non-T2D group, 7.5 fold higher (OR 7.5, IC 95% 5.2–10.7) in patients who remained in WL vs KT, 
and 18.5 fold higher (OR 18.5, IC 95% 4.9–10.1) for the group with lower survival (non-transplanted patients 
in T2D group) vs patients with favorable one (non-T2D who underwent KT).
A stratification of survival analysis in T2D group revealed the significant negative impact of an history of 
vascular accident (intended as PCI, CABG and/or cerebrovascular accident) on this population (Supplementary 
Figure S1, p = 0.015); also insulin therapy and a worst glycemic control showed a negative trend on patients 
survival (Supplementary Figures S2 and S3).
Figure 1.  Survival analysis in the overall population (Kaplan–Meyer) according to T2D presence/absence. 
Follow/up start in (a) at the beginning of dialysis or in (b) at time of registration in WL.
Figure 2.  Survival analysis in the overall population (Kaplan–Meyer) according to kidney transplantation or 
maintenance on WL. Follow/up start in (a) at the beginning of dialysis or in (b) at time of registration in WL.
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Waiting list period. The median waiting time for KT was not statistically different between T2D and non-
T2D group [466.5 days (25° 104.5–75° 1182) vs 620 (25° 174–75° 1619) respectively, p = 0.095].
Despite the percentage of patients who experienced at least one temporary suspension from the WL was quite 
similar in T2D and non-T2D (36% vs 39.7% respectively; p = 0.3), the period of suspension was longer in T2D 
group (571 days, 25° 289–75° 1073 vs 257, 25° 83.5–75° 802; p < 0.001). T2D group also experienced an higher 
percentage of patients definitively dropped out from WL for clinical reasons (17.4% vs 8.4%, p = 0.008) and a 
longer time elapsed between dialysis start and WL registration (1.6 years, 25° 1.1–75° 2.5 vs 1.2, 25° 0.72–75° 
2.2; p = 0.008) (Table 1).
Discussion
T2D is now considered the leading cause of ESKD in western countries, with a percentage of affected patients 
that range from 30% in European  area2,9 to 45% in  USA10,11. In our population the prevalence of T2D in dialytic 
population significantly increased over time, from 25% (2004–2008) to 29.1% (2009–2013)2. In subjects who 
ultimately needed renal-replacement therapies, T2D also negatively affect patient  survival12. In 2009 Report of 
United States Renal Data system the 10-year survival of T2D patient on hemodialysis stands around 10%13; in 
another study in France 32% of patients with T2D died after a mean f/up of about 7 months14.
Despite its increasing incidence, the proportion of T2D patients admitted to WL is relatively low (ranging 
from 15–20% in Europe to about 30% in USA) as reported in  literature5,15–20, and confirmed in our experience.
The prevalence of T2D among dialytic population in our region where KT Center is located (Piemonte e Valle 
d’Aosta) is about 29%2; however, considering the average age of patients who started dialysis (≈ 70 years)21, it is 
conceivable that only a portion of these T2D patients would be considered eligible for KT.
This difference is probably referred to T2D-related comorbidities (i.e. CAD, peripheral vascular disease, infec-
tions) who may determine an a-priori exclusion or a delay/interruption in WL process for acute clinical events 
Figure 3.  Survival analysis in T2D (a, b) and non-T2D (c, d) group (Kaplan–Meyer) according to kidney 
transplantation or maintenance on WL. Follow/up start in (a) and (c) at the beginning of dialysis or in (b) and 
(d) at time of registration in WL.
Table 3.  Cause of death in waitlisted patients who not received KT according to T2D presence/absence.
T2D (n = 15) Non-T2D (n = 43) p
Cardiovascular events, n (%) 8 (53.3) 19 (44.2)
0.455
Infection, n (%) 4 (26.7) 11 (25.6)
Tumors, n (%) 2 (13.3) 2 (4.7)
Other, n (%) 1 (6.7) 6 (14)
Not specified, n (%) 0 (0) 5 (11.6)
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(i.e. conditions requiring surgical or angiographic procedures as coronary artery intervention). A demonstration 
derived from the paper by Villar et al.5 where T2D and elderly age (> 60 years) are identified as the leading causes 
for WL exclusion, and both elderly and diabetic patients need a longer time for the pre-transplantation balance.
Data are still lacking about morbidity and mortality in the subgroup of T2D patients considered eligible for 
WL. Schold et al.22 reported that T2D patients are more prone to be removed from WL and Ningyan et al.23 
underlined that a great proportion of patients were dropped-out from WL due to a cardiovascular event, a con-
dition extensively related to T2D.
In our analysis, as expected, T2D patients at the time of WL registration were older, with higher BMI and more 
frequent history of CAD and peripheral vascular disease. Despite the pre-admission balance demonstrates that 
the majority of patients had a normal ejection fraction and were on-target for HbA1c according to international 
 guidelines24, our adjunctive analysis revealed the significant role of an history of vascular accident on reducing 
patient survival, with also a univocal trend for patients with poor glycemic control: all these information stressed 
the importance of good T2D management also in the subgroup of patients admitted to WL.
As also expected, KT determined a significant outcome amelioration in both T2D and non- T2D group. 
Many studies showed similar  results4,25 also suggesting an adjunctive benefit for pre-emptive  transplantation26,27. 
Despite slightly better results were observed in non-T2D group, as outlined by Cosio et al.6 mortality in KT 
recipients with T2D has progressively declined over time, thanks to the improvements in the management of both 
T2D and KT, and the beneficial effect of KT as also observed in our population is overwhelming. In accordance 
with K-DOQI guidelines all ESKD patients, especially those with T2D, need to be referred to a nephrological 
center also for a prompt pre-transplant  evaluation28.
On the other hand, despite patients in T2D and non-T2D group have a similar median WL-time and percent-
age of temporary drop-out from WL, transplant rate was lower in T2D patients; moreover, T2D experienced a 
threefold higher mortality after waitlisting which remained extremely high in not transplanted patients, sus-
pension periods were longer and associated with a higher definitive drop-out rate in T2D group suggesting a 
significant negative impact of T2D-related comorbidities. Previous studies identify T2D and cardiovascular 
disease as major dominants of lower odds of being on the  WL29–31.
Similar to Lee et al.8 T2D patients experienced a higher mortality during WL also in our study and, as 
expected, cardiovascular events (probably underestimated due to the absence of a determined death cause in 
the majority of patients) were the most common cause of death in this group. Cardiovascular disease are typical 
comorbidities affecting all ESKD patients, with higher prevalence and incidence than in general population: they 
can aggravate the underlying medical condition and limit the access to  KT7. Successful KT accords major benefits 
by reducing cardiovascular risk in these patients, and efforts are needed to minimize WL  time32.
Based on our study design, not influenced by a negative-selection bias, we speculate that the reduced likeli-
hood of KT among T2D group may also suggest a per-se negative effect of T2D on KT rate. In one recent study 
by Jeon et al. the occurrence of cardiovascular disease but not diabetes determined lower transplant  rates7, so it 
could be important to investigate the possible negative T2D effect in larger cohorts.
Despite the obvious limitations (low percentage of T2D patients admitted to WL, retrospective design) 
which also affected the majority of the reported experiences in this area, our study demonstrates that (a) T2D 
significantly affects patients survival also on patients who are eligible for WL (b) T2D patients, probably due to 
T2D-related conditions (especially vascular disease), have a reduced probability of being transplanted (c) KT also 
in T2D patients is clearly associated with better survival. In our opinion efforts are needed in order to estimate 
as earlier as possible the eligibility of T2D patients for WL and, at the same time, allocation policies may be 
adjusted according to the increased risk of mortality and WL suspension due to comorbidities in T2D patients.
Methods
Retrospective study on the waitlisted population of our center (Renal Transplantation Center “A. Vercellone”, 
Turin, Italy) including all patients who are considered eligible and included in active WL in the period between 
January 2005 and December 2010, and transplanted until February 2016. The analysis included patients from 
two regions of northern Italy (Piemonte and Valle d’Aosta) and at first KT; type 1 and post-transplant diabetes 
mellitus, and patients with glycated hemoglobin (HbA1c) > 64 mmol/mol at the time of inclusion in WL were 
excluded. Diagnosis of T2D was made according to the American Diabetes Association  recommendations24. 
Recorded variables at registration in WL included age, sex, dialysis duration and modality (hemodialysis or peri-
toneal dialysis), body mass index (BMI), history of coronary artery (CAD) and/or peripheral vascular disease. 
All these conditions were compared to T2D presence/absence. Data were collected from the database of our 
transplantation center (ITR02, Dialysis and Transplantation Registry of Piemonte) and are thereafter elaborated 
in anonymous format. This study is covered by Ethical Committee approval, resolution number 1449/2019 on 
11/08/2019 ("TGT" observational study).
Statistical analysis was performed with SPSS (IBM SPSS Statistics, vers.25.0.0). Continuous variables are 
presented as mean ± standard deviation or as median (25°-75° percentile), according to their distribution ana-
lysed with Kolmogorov–Smirnov test. The difference between groups was analysed, respectively, with t-test or 
Mann–Whitney test. Some cut-off levels were with ROC curves. Categorical variables are presented as fraction 
and Pearson’s or, for small samples, Fisher’s exact test was employed to compare groups. The odds ratios (OR) with 
95% Confidence Interval were used as a measure of relative risk. Univariate Survival analysis was performed by 
means of the Kaplan–Meier method with Log Rank test to compare strata. Cox proportional-hazards model was 
used to investigate the association between the survival time of patients and predictor variables. Significance 
level for all tests was set at p < 0.05.
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Ethical statement. This study is covered by Ethical Committee approval, Resolution Number 1449/2019 
on 11/08/2019 ("TGT" observational study) for which all patients sign an informed consent. The study was con-
ducted in accordance with Declaration of Helsinki.
Data availability
All data and datasets used and/or analysed during the current study are available from the corresponding author 
on reasonable request.
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